Target intelligence / Profile preview

Influenza virus hemagglutinin stalk domain (HA stalk)

Target
HA stalk
Molecular classification
Viral protein domain, Fusion protein domain (viral), Envelope glycoprotein subdomain, Other (if specifically required: trimeric viral fusion protein subregion)
01

Overview

The influenza virus hemagglutinin stalk domain is the highly conserved structural region at the base of hemagglutinin (HA), the major surface glycoprotein of influenza viruses. HA is synthesized as a precursor (HA0) and cleaved into HA1 (globular head) and HA2 (stalk), with the stalk composed of most or all of HA2 and portions of HA1. The stalk domain supports the head, mediates pH-triggered conformational changes that drive membrane fusion for viral entry, and contains conserved epitopes targeted by broadly neutralizing antibodies. Unlike the variable globular head, the stalk domain is relatively conserved across influenza subtypes, making it a promising target for universal vaccine and antibody therapies. Broadly neutralizing antibodies can bind the stalk, locking HA in its pre-fusion state and preventing infection. The stalk domain is critical for both viral infectivity and as a focus for next-generation anti-influenza interventions.

Other names
Hemagglutinin stemHA stemStalk domain of hemagglutininInfluenza hemagglutinin stalk
02

Mechanism of action

Neutralizing antibodies: Bind to conserved stalk epitope, inhibit conformational changes necessary for membrane fusion, block viral entry Small-molecule inhibitors: Stabilize pre-fusion conformation, block membrane fusion process

03

Biological functions

Membrane fusion (virus–host cell entry)Structural stability of hemagglutinin trimerAntigenicity (conserved epitope for neutralizing antibodies)Mediates conformational changes required for viral and endosomal membrane fusion
04

Disease associations

Infection (influenza)Target for broad-spectrum influenza prevention and therapy (universal vaccines)Other viral infections utilizing similar stalk/stem regions for entry may show analogous roles
05

Safety considerations

Potential for viral escape mutations at stalk epitope that can reduce efficacy of antibodiesCross-reactive immune responses with potential off-target effects (rare; theoretical)
06

Interacting drugs

Broadly neutralizing antibodies (bnAbs; e.g., CR6261, FI6v3, MEDI8852)

1 more in the full profile.

07

Biomarkers

Presence/titer of anti-HA stalk antibodies (predicts broad protection against diverse influenza strains)Seroconversion to stalk-specific epitopes (in vaccine studies)

Beyond the preview

Go deeper on Influenza virus hemagglutinin stalk domain (HA stalk).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza virus hemagglutinin stalk domain (HA stalk).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call